FindTrial
Sign In

Evaluation of additional intraocular pressure reduction with once daily, evening administration of travoprost 0.004%, once daily, evening administration of travoprost 0.004%/timolol 0.5% fixed combination and once daily, evening administration of travoprost 0.004%/timolol 0.5% fixed combination plus twice daily brinzolamide 1% in open angle glaucoma

Evaluation of additional intraocular pressure reduction with once daily, evening administration of travoprost 0.004%, once daily, evening administration of travoprost 0.004%/timolol 0.5% fixed combination and once daily, evening administration of travoprost 0.004%/timolol 0.5% fixed combination plus twice daily brinzolamide 1% in open angle glaucoma

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-000811-27-HU
Enrollment
Unknown
Registered
2007-03-21
Start date
2007-05-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle glaucoma

Interventions

Trade Name: Travatan Pharmaceutical Form: Eye drops, solution Trade Name: Azopt Pharmaceutical Form: Eye drops, suspension Trade Name: Duotrav Pharmaceutical Form: Eye drops, solution

Sponsors

Department of Ophthalmology, SEmmelweis University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Chronic open-angle galucoma in adults (older than 18 y) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Other eye diseases, contraindications against beta-blockers and sulfonamides, lactation and pregnancy

Design outcomes

Primary

MeasureTime frame
Main Objective: To investigate additional IOP decrease in a tripple combination of IOP lowering medications;Secondary Objective: ;Primary end point(s): IOP lowering at each 4 week period of the treatment—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026